Clinical Trial Update: Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib for COVID-19–induced acute respiratory distress syndrome (ARDS) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Philipps University Marburg | Conditions: ARDS, Human, COVID | Phase 2 | Status: COMPLETED